Douglas J Swirsky bought $65k of MXCT
CHIEF FINANCIAL OFFICER at MAXCYTE, INC.. 50,000 shares at an average of $1.29, traded Aug 13, 2025, filed Aug 13, 2025.
Score components
- +22RoleCFO
- +8Trade size$64k at market
- +6Relative to holdingsHoldings up 45%
- +18Price context9% above the 52-week low; 73% below the 52-week high
- +15Cluster5 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000905148-25-002877, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Aug 13, 2025 | POpen-market purchase Common Stock | +50,000 | $1.29 | $65k | 161,811 | Aug 13, 2025 |
Related signals
Other insiders at MAXCYTE, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 22Weak | MXCTsell MAXCYTE, INC. | Douglas J Swirsky CHIEF FINANCIAL OFFICER | $8,266 10,142 shares | -6% | |
| 0Weak | MAXCYTE, INC. | Rekha Hemrajani director | $22k 10,684 shares | -21% | |
| 62Notable | MAXCYTE, INC. | William W Brooke director | $65k 50,000 shares | +50% | |
| 68Notable | MAXCYTE, INC. | Richard Douglas director | $111k 80,000 shares | +53% | |
| 65Notable | MAXCYTE, INC. | Stanley C Erck director | $137k 100,000 shares | +34% | |
| 78Notable | MAXCYTE, INC. | Maher Masoud President and CEO | $103k 75,000 shares | +75% | |
| 0Weak | MAXCYTE, INC. | John Joseph Johnston director | $14k 3,000 shares | -2% | |
| 0Weak | MAXCYTE, INC. | John Joseph Johnston director | $12k 3,000 shares | -2% | |
| 0Weak | MAXCYTE, INC. | John Joseph Johnston director | $11k 3,000 shares | -2% | |
| 5Weak | MAXCYTE, INC. | Stanley C Erck director | $177k 47,689 shares | -15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.